Bristol Myers Squibb Long Term Debt 2010-2022 | BMY

Bristol Myers Squibb long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
  • Bristol Myers Squibb long term debt for the quarter ending June 30, 2022 was $37.107B, a 12.7% decline year-over-year.
  • Bristol Myers Squibb long term debt for 2021 was $39.605B, a 18.06% decline from 2020.
  • Bristol Myers Squibb long term debt for 2020 was $48.336B, a 11.41% increase from 2019.
  • Bristol Myers Squibb long term debt for 2019 was $43.387B, a 668.46% increase from 2018.
Bristol Myers Squibb Annual Long Term Debt
(Millions of US $)
2021 $39,605
2020 $48,336
2019 $43,387
2018 $5,646
2017 $6,975
2016 $5,716
2015 $6,550
2014 $7,242
2013 $7,981
2012 $6,568
2011 $5,376
2010 $5,328
2009 $6,130
Bristol Myers Squibb Quarterly Long Term Debt
(Millions of US $)
2022-06-30 $37,107
2022-03-31 $37,450
2021-12-31 $39,605
2021-09-30 $39,677
2021-06-30 $42,503
2021-03-31 $44,505
2020-12-31 $48,336
2020-09-30 $41,364
2020-06-30 $41,853
2020-03-31 $42,844
2019-12-31 $43,387
2019-09-30 $24,390
2019-06-30 $24,433
2019-03-31 $5,635
2018-12-31 $5,646
2018-09-30 $5,687
2018-06-30 $5,671
2018-03-31 $5,775
2017-12-31 $6,975
2017-09-30 $6,982
2017-06-30 $6,911
2017-03-31 $7,237
2016-12-31 $5,716
2016-09-30 $5,836
2016-06-30 $6,581
2016-03-31 $6,593
2015-12-31 $6,550
2015-09-30 $6,632
2015-06-30 $6,615
2015-03-31 $7,127
2014-12-31 $7,242
2014-09-30 $7,267
2014-06-30 $7,372
2014-03-31 $7,367
2013-12-31 $7,981
2013-09-30 $6,532
2013-06-30 $6,442
2013-03-31 $6,522
2012-12-31 $6,568
2012-09-30 $6,608
2012-06-30 $5,209
2012-03-31 $5,270
2011-12-31 $5,376
2011-09-30 $5,437
2011-06-30 $5,332
2011-03-31 $5,276
2010-12-31 $5,328
2010-09-30 $6,479
2010-06-30 $6,248
2010-03-31 $6,081
2009-12-31 $6,130
2009-09-30 $6,307
2009-06-30 $6,235
2009-03-31 $6,492
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $160.059B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $81.408B 9.78
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.018B 18.45
Biohaven Pharmaceutical Holding (BHVN) United States $10.535B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.821B 35.53
Myovant Sciences (MYOV) United Kingdom $1.600B 0.00
Emergent Biosolutions (EBS) United States $1.482B 8.59
Zymeworks (ZYME) Canada $0.390B 0.00
Enzo Biochem (ENZ) United States $0.120B 0.00
Gelesis Holdings (GLS) United States $0.104B 0.00
SQZ Biotechnologies (SQZ) United States $0.097B 0.00
Ambrx Biopharma (AMAM) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00